Ketoprofen: profile and news
Velcade Lung Cancer Study Begins 07 Mar 2006
...by the Food and Drug Administration to treat the blood cancer multiple myeloma, is also being studied to treat other lung cancers combined with Tarceva, a drug ... - TheStreet.com
OSI Pharma Updates 2005 Tarceva Sales Feb 1, 2006
...updated total sales for cancer drug Tarceva Wednesday after partner Roche Holding Ltd. ... In 2005, US Tarceva sales totaled $274.9 million. ... - Houston Chronicle,
OSI says Tarceva international Q4 sales reach $25 mln Feb 1, 2006
...(OSIP.O: Quote, Profile, Research) said on Wednesday international sales of lung cancer drug Tarceva reached $25 million in the fourth quarter. ... - Reuters
OSI Pharmaceuticals Announces Fourth Quarter Net Sales for Tarceva ... Feb 1, 2006
OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today announced fourth quarter international sales for its flagship product, Tarceva(R) (erlotinib). ... - Genetic Engineering News,
OSI Pharmaceuticals to Webcast its R&D Day on Friday, March 10 ... Mar 1, 2006
OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have ... - PharmaLive.com (press release),
SunTrust Boosts OSI Pharma To Buy From Neutral Feb 23, 2006
The analyst said "the negative sentiment towards the acquisition has run its course and investors have begun to refocus on Tarceva and Macugen sales.". ... - New Ratings
The Four Major Cancer Markets, Which Include Colorectal, Prostate ... Mar 2, 2006
Continued uptake of Tarceva and potential approvals for Avastin, Zactima, Erbitux and other new therapies will offset the decline in value that has come as a ... - Genetic Engineering News,
Genes May Influence Response to Brain-Tumor Treatments Feb 26, 2006
Two drugs, Tarceva (erlotinib) and Iressa (gefitinib), have had some success in treating glioblastomas and have been approved for treating advanced lung cancer ... - Online - International News Network,
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
Down the line, Genentech’s Tarceva (erlotinib), which sold $274.9 million last year, could also compete in colorectal cancer. ... - BioWorld Online (subscription),
Monogram Announces Year End 2005 Financial Results Feb 22, 2006
...assays by analyzing patient tumor samples taken from patients prior to treatment with the EGFR/HER inhibitor drugs: Herceptin(R), Iressa(R), Tarceva(TM) and ... - MSN Money
The Cancer That Won't Quit Feb 20, 2006
Last November, Tarceva, a drug developed by OSI Pharmaceuticals (OSIP:Nasdaq - commentary - research - Cramer's Take) and co-marketed with Genentech (DNA:NYSE ... - TheStreet.com
Inflation Fears Linger Mar 3, 2006
On January 11th, 2006, OSI Pharmaceuticals said its fourth quarter net US sales rose to $83.9 million and net sales of its flagship product, Tarceva, rose 15%. ... - Trading Markets,
Cancer: we can control it but you can't afford it Feb 11, 2006
Last week Sikora prescribed the cancer drug Tarceva, which is not routinely available on the NHS, privately to a young patient suffering from pancreatic cancer ... - The Sunday Times,
Vital pill cost my house Feb 6, 2006
...lottery. The 68-year-old’s only hope is a wonder drug called Tarceva — but it is only freely available on the NHS in Scotland. ... - The Sun,
Pancreatic cancer a ’silent’ disease Feb 13, 2006
...life marked promising milestones in recent months, including the Food and Drug Administration’s approval in November of the lung cancer drug Tarceva for use ... - Ocala.com,
OSI Pharmaceuticals to Webcast its R&D Day on Friday, March 10 ... Mar 1, 2006
OSI'sflagship product, Tarceva(R) (erlotinib), is the first drug discoveredand developed by OSI to obtain FDA approval and the only EGFRinhibitor to have ... - Finanzen.net,
Recruitment Temporarily Suspended in an International Phase III ... Feb 12, 2006
Genentech is leading clinical development programs for Rituxan(R) (Rituximab), Herceptin(R) (Trastuzumab), Avastin(R) (bevacizumab), and Tarceva(R) (erlotinib ... - PR Newswire (press release),
Recruitment Temporarily Suspended in an International Phase III ... Feb 12, 2006
...is leading clinical development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab), Avastin® (bevacizumab), and Tarceva® (erlotinib), and markets ... - Yahoo! News (press release)
Cancer drug's new use — at a price Feb 15, 2006
Ellis Minrath, who has pancreatic cancer, said he had chosen not to take Tarceva, a drug from Genentech that is approved for lung cancer and has shown promise ... - International Herald Tribune,
Biotechs ape pharma strategy as profits grow Feb 24, 2006
OSI Pharmaceuticals Inc. (OSIP.O: Quote, Profile, Research), whose growth engine is the cancer drug Tarceva, generated a firestorm of opposition from ... - Reuters
Anti-angiogenesis Therapy With Avastin (Bevacizumab): Presented at ... Feb 21, 2006
...advanced/recurrent malignant breast cancer, in combination with a number of other therapeutic agents, including vinorelbine, docetaxel, Tarceva(R) (erlotinib ... - DG News
Health care: Lessons from Great Britain Feb 22, 2006
Geraldine Smith (Labour): "More than 100 cancer patients now receive the licensed drug Tarceva, but Morecambe Bay NHS Primary Care Trust refuses to prescribe ... - Arkansas News,
CORRECT: Roche sales rise 19% on flu, cancer drugs Feb 1, 2006
Growth in the pharmaceutical division was boosted by strong sales of cancer treatments Avastin and Tarceva as well as Hepatitis B and C drug Pegasys. ... - Investor's Business Daily (subscription)
Roche shines in its annual operations Feb 1, 2006
Growth was fuelled by strong demand for the division's flagship oncology portfolio, now boosted by cancer treatments Avastin and Tarceva, by strong sales of ... - Swissinfo,
Roche 2005: Record Sales and Operating Profit Feb 1, 2006
...driven primarily by strong demand for the division’s flagship oncology portfolio, now boosted by the innovative cancer treatments Avastin and Tarceva, and by ... - PharmaLive.com (press release),
OSI Pharmaceuticals Announces European Regulatory Approval for ... Feb 2, 2006
OSI's flagship product, Tarceva(R)(erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have ... - Genetic Engineering News,
Give Us All Wonder Drugs Now ; RIVALS GANG UP ON HEALTH MINISTER ... Feb 7, 2006
COST slightly less than pounds 30,000 per person per year. TARCEVA for non-small cell lung cancer, but waiting Nice approval. COST ... - International News Service,
Give us all wonder drugs now Feb 7, 2006
COST slightly less than £30,000 per person per year. TARCEVA for non-small cell lung cancer, but waiting Nice approval. COST £600 every three weeks. - ic NorthWales,
What's It Worth to You? Feb 16, 2006
We're going to have to. "Ellis Minrath, who has pancreatic cancer, said he had chosen not to take Tarceva, a drug from Genentech that is approved for lung ... - Corante,
Genzyme Launches Key Test to Monitor Gleevec(R) Resistance Feb 9, 2006
...of epidermal growth factor receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva(R) (erlotinib) and ... - International News Service,
Ambit Biosciences Expands Kinase Profiling Panel to 234 Kinases ... Feb 14, 2006
With more than 30 kinase inhibitors in clinical trials or approved for human use including Gleevec(R), IRESSA(R) and TARCEVA(TM), this important class of ... - Genetic Engineering News,
R&D Business Feb 16, 2006
Revenue will be driven by strong growth of Herceptin, Tarceva, MabThera, and Avastin, all cancer products Roche markets through its relationship with Genentech ... - R&D Directions (subscription),
Reply to the Editor Feb 14, 2006
However, inhibitors of receptor tyrosine kinases such as epidermal growth factor receptor (Iressa, Tarceva) and platelet-derived growth factor receptor (Gleevec ... - The Journal of Thoracic and Cardiovascular Surgery
Singular focus Feb 5, 2006
...individuals depending on their genomic variations: Novartis Pharmaceutical Corp.’s Gleevec for chronic myeloid leukemia; Genentech Inc.’s Tarceva, for lung ... - Worcester Telegram (subscription),
In my own words: Incurable? Feb 6, 2006
2004. After chemo, radiation and taking a drug called Tarceva for 6 months, she was told in November that she was in full remission. ... - Naples Daily News (subscription),
Genzyme launches test to monitor Gleevec resistance Feb 13, 2006
...of epidermal growth factor receptor (EGFR) mutations have been shown to correlate with clinical response to certain drugs, including Tarceva (erlotinib) and ... - News-Medical.net,
Cancer and bird flu drugs drive record sales at Roche Feb 1, 2006
Cancer drug sales were up 42 per cent to SFr11bn as new treatments such as Avastin and Tarceva more than made up for declining sales of former blockbuster ... - MSN Money
TEXT-S&P rates Roche Holding AG AA+/A-1+; outlook stable Jan 31, 2006
...portfolio, which was boosted by the two recent market approvals of anti-cancer drugs Avastin, approved in the US in February 2004, and Tarceva, approved in the ... - Reuters
Drugs for cancer easy to get in BC Feb 1, 2006
In Ontario, for example, Velcade does not have full, approved funding to treat a relapse of multiple myeloma, nor does Tarceva for non-small-cell lung cancer ... - Globe and Mail,
